Rational use of medicines -: an important issue in pharmaceutical policy

被引:29
作者
Almarsdóttir, AB
Traulsen, JM
机构
[1] Univ Iceland, Fac Pharm, AL BAS Pharmaceut Consultants Ltd, IS-107 Reykjavik, Iceland
[2] Danish Univ Pharmaceut Sci, Dept Social Pharm, DK-2100 Copenhagen, Denmark
来源
PHARMACY WORLD & SCIENCE | 2005年 / 27卷 / 02期
关键词
clinical pharmacy; drug utilisation; medicine management; pharmaceutical care; pharmaceutical policy; rational medicine use;
D O I
10.1007/s11096-005-3303-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this article the authors deal with issues of drug utilisation from a clinical and policy perspective. They address the difficulties of managing drug therapy on a population level, which is known among professionals, as the problem of rational use of medicines. Various definitions and interpretations are presented and compared. This is followed by a presentation of the concerns associated with pharmaceutical marketing from a policy perspective, including the fear that the dominance of information produced by industry may lead to irrational drug use. Next, the authors review the tools for policy making including educational, managerial, and regulatory interventions. The (often overlapping) concepts of medicines management, clinical pharmacy and pharmaceutical care are then discussed to show how professionals, sometimes in collaboration with policymakers, have tackled the problem of nonrational use of medicines. The authors address the question as to whether the rational use of medicines a universal concept, whether it can be and whether it should be? They argue that, as with most concepts, the rational use of medicines must always be viewed in context. They conclude that pharmacy needs to adapt its way of thinking to include the issue of context. They point out that clinical pharmacists today already adapt their decisons to each patient and patient group. Policymakers are encouraged to adopt a similar approach because populations as well as particular market situations vary and therefore policy solutions cannot be considered universal.
引用
收藏
页码:76 / 80
页数:5
相关论文
共 30 条
[1]  
*ACCP, 2004, ACCP REPORT, V23
[2]   A lay prescription for tailor-made drugs -: focus group reflections on pharmacogenomics [J].
Almarsdóttir, AB ;
Björnsdóttir, I ;
Traulsen, JM .
HEALTH POLICY, 2005, 71 (02) :233-241
[3]  
[Anonymous], 2001, SPOONF SUG MED MAN N
[4]  
[Anonymous], WHAT IS CLIN PHARM
[5]  
Armstrong D, 1996, BRIT MED J, V312, P949
[6]   SCIENTIFIC VERSUS COMMERCIAL SOURCES OF INFLUENCE ON THE PRESCRIBING BEHAVIOR OF PHYSICIANS [J].
AVORN, J ;
CHEN, M ;
HARTLEY, R .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (01) :4-8
[7]   Pharmaceutical care and medicines management - is there a difference? [J].
Barber, N .
PHARMACY WORLD & SCIENCE, 2001, 23 (06) :210-211
[8]  
BRODIE DC, 1980, AM J PHARM EDUC, V44, P276
[9]  
Cipolle RJ, 2004, PHARM CARE PRACTICE
[10]   Attitudinal barriers to delivery of race-targeted pharmacogenomics among informed lay persons [J].
Condit, C ;
Templeton, A ;
Bates, BR ;
Bevan, JL ;
Harris, TM .
GENETICS IN MEDICINE, 2003, 5 (05) :385-392